Description / Application
SLC-0111 is it is a potent carbonic anhydrase inhibitor (Ki = 45.1 nM and 4.5 nM for CA IX and CA XII, respectively) that is in clinical trials for the treatment of hypoxic malignancies. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor and an antineoplastic agent. It is a member of phenylureas, a sulfonamide and a member of monofluorobenzenes.
Identities
| Alternative Name | 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzenesulfonamide, NSC 213841 |
|---|---|
| Molecular Formula | C13H12FN3O3S |
| Molecular Weight | 309.32 |
| MFCD | MFCD00159265 |
Safety
| Pictograms |
|
|---|---|
| Signal Word | Warning |
| Hazard Statements | H319 |
| Precautionary Statements | P264;P280;P305+P351+P338;P337+P313 |